The influence of p16 immunohistochemistry on diagnosis and management recommendation of melanocytic neoplasms by dermatopathologists: A prospective study

J Cutan Pathol. 2021 Aug;48(8):1094-1097. doi: 10.1111/cup.13907. Epub 2020 Nov 20.

Authors

Jessica R Terrell¹, Iryna Rybak¹, Yue Lyu², Thomas Konia^{1

3}, Maxwell A Fung^{1

3}, Lihong Qi⁴, Maija Kiuru^{1

3}

Affiliations

¹ Department of Dermatology, University of California, Sacramento, California, USA.
² Department of Statistics, University of California, Sacramento, California, USA.
³ Department of Pathology and Laboratory Medicine, University of California, Sacramento, California, USA.
⁴ Department of Public Health Sciences, University of California, Sacramento, California, USA.

No abstract available

MeSH terms

Biomarkers, Tumor / analysis
Cyclin-Dependent Kinase Inhibitor p16 / genetics*
Cyclin-Dependent Kinase Inhibitor p16 / metabolism
Dermatology / standards
Disease Management
Early Detection of Cancer / methods
Humans
Immunohistochemistry / methods*
Melanoma / diagnosis*
Melanoma / metabolism
Melanoma / therapy
Pathology / standards
Prospective Studies
Skin Neoplasms / pathology*

Substances

Biomarkers, Tumor
Cyclin-Dependent Kinase Inhibitor p16

Grants and funding